Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Opinion Editor's Corner ESC 2016

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

Shelley Wood

September 08, 2016

Presentation ESC 2016

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Presenter: Zuzana Motovska

August 30, 2016

News Conference News ESC 2016

Prasugrel, Ticagrelor Give Similar Short-term Outcomes After Primary PCI: PRAGUE-18

Todd Neale

August 30, 2016

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Todd Neale

August 28, 2016

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

Prehospital Administration of Ticagrelor Cuts Early Ischemic Events in STEMI Patients

L.A. McKeown

September 01, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2014

ESC Congress 2014: Positive, Negative Findings Come on Background of Improving Outcomes Overall

Todd Neale

September 08, 2014

News Conference News ESC 2014

ACCOAST Substudy: Prasugrel Pretreatment Linked With Increased Bleeding in NSTEMI Patients

Yael L. Maxwell

September 03, 2014

Presentation ESC 2014

Predictors of Bleeding in ACS Patients Treated With Prasugrel: Analysis From the ACCOAST Study

Presenter: Petr Widimsky

September 02, 2014

News Conference News ESC 2014

ATLANTIC: Prehospital Ticagrelor Safe in STEMI, But No Added Benefit Compared With In-Hospital Administration

Yael L. Maxwell

September 01, 2014

News Conference News ESC 2013

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

September 09, 2013

News Conference News ESC 2013

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Yael L. Maxwell

September 03, 2013

News Conference News ESC 2013

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

Caitlin E. Cox

September 01, 2013

News Conference News ESC 2013

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Yael L. Maxwell

September 01, 2013

News Conference News ESC 2012

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Caitlin E. Cox

September 04, 2012

Presentation ESC 2012

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial

Presenter: Matthew Roe

August 28, 2012

Advertisement

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Prasugrel, Ticagrelor Give Similar Short-term Outcomes After Primary PCI: PRAGUE-18

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Prehospital Administration of Ticagrelor Cuts Early Ischemic Events in STEMI Patients

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

ESC Congress 2014: Positive, Negative Findings Come on Background of Improving Outcomes Overall

ACCOAST Substudy: Prasugrel Pretreatment Linked With Increased Bleeding in NSTEMI Patients

Predictors of Bleeding in ACS Patients Treated With Prasugrel: Analysis From the ACCOAST Study

ATLANTIC: Prehospital Ticagrelor Safe in STEMI, But No Added Benefit Compared With In-Hospital Administration

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content